



PHARMACEUTICAL QUALITY INVESTIGATION BRANCH
19701 Fairchild
Irvine, CA 92612
United States

Via UPS
Return Receipt Requested

www.fda.gov

10/23/2018

Mr. Navin Karnani
Site Director
Deccan Nutraceuticals PVT LTD
1065 Golegaon Road, Off Alandi Markal Rd
Markal, Maharashtra, 412105 India

Dear Mr. Karnani:

The U.S. Food and Drug Administration (FDA) conducted an inspection at Deccan Nutraceuticals PVT LTD, FEI:3007607026, located at 1065 Golegaon Road, Off Alandi Markal Rd, Markal, Maharashtra 412105 IN from 08/06/2018 - 08/10/2018. FDA has determined that the inspection classification of this facility is "voluntary action indicated" ("VAI").¹ Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regards to current good manufacturing practice (CGMP).

A VAI inspection classification indicates that, although investigators found and documented objectionable conditions during the inspection, FDA will not take or recommend regulatory or enforcement action because the objectionable conditions do not meet the threshold for action at this time. Despite this facility inspection classification, FDA recommends that you address any observations noted on the Form FDA 483 issued at the the conclusion of the inspection or otherwise conveyed to you following the inspection. If not corrected, the same or similar conditions could lead to a future inspection being classified as "official action indicated" ("OAI").

This letter is not intended as an endorsement or certification of the facility. It remains your responsibility to ensure continued compliance with CGMP.

An inspection classification of VAI for CGMP compliance will not directly negatively impact FDA's assessment of any pending marketing application referencing this facility. Please note, however, that application approval will depend on a product-and application-specific facility assessment conducted by CDER's Office of Pharmaceutical Quality. This letter does not address or reflect FDA's decision making with respect to any potential non-CGMP compliance issues.

FDA has concluded that this inspection is "closed" under 21 CFR 20.64(d)(3), and we are enclosing a copy of the narrative portion of the Establishment Inspection Report (EIR). It may reflect redactions made by FDA in accordance with the Freedom of Information Act (FOIA) and 21 CFR part 20. This, however, does not preclude you from requesting additional information under FOIA.

If you have any questions regarding this letter, you may contact me via telephone at (949) 608-3519 or email at Katherine.Jacobitz@FDA.HHS.GOV.

Sincerely,

Nalini D. Lebzelter -S

Digitally signed by Nalini D. Lebzelter -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People,
ou=2342-18200300-100-1, +2000337778, cn=Nalini D. Lebzelter
-S
Date: 2018.10.26 10:30:33 -0800

Nalini Lebzelter, Acting Director, Investigations Branch,
for CAPT Katherine E. Jacobitz, Director, Investigations Branch,
Division IV, Office of Pharmaceutical Quality Operations

¹ See Inspection Classification Definitions, at <https://www.fda.gov/ICECI/Inspections/ucm223231.htm>.